Mair Grant, von Kummer Rüdiger, Lindley Richard I, Sandercock Peter A G, Wardlaw Joanna M
Division of Neuroimaging Sciences, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.
Department of Neuroradiology, Dresden University Stroke Centre, University Hospital, Dresden, Germany.
PLoS One. 2015 Dec 23;10(12):e0145683. doi: 10.1371/journal.pone.0145683. eCollection 2015.
To assess whether the x-ray attenuation of intra-arterial obstruction measured on non-contrast CT in ischemic stroke can predict response to thrombolysis and subsequent functional outcome.
The Third International Stroke Trial (IST-3) was a multicenter randomized-controlled trial of intravenous thrombolysis (rt-PA) given within six hours of ischemic stroke. Ethical approval and informed consent were obtained. In a subgroup of 109 IST-3 patients (38 men, median age 82 years), a single reader, masked to all clinical and other imaging data, manually measured x-ray attenuation (Hounsfield Units, HU) on non-contrast CT at the location of angiographically-proven intra-arterial obstructions, pre-randomization and at 24-48 hour follow-up. We calculated change in attenuation between scans. We assessed the impact of pre-randomization arterial obstruction attenuation on six-month functional outcome.
Most arterial obstructions (64/109, 59%) were hyperattenuating (mean 51.0 HU). Compared with control, treatment with rt-PA was associated with a greater, but non-significant, reduction in obstruction attenuation at follow-up (-8.0 HU versus -1.4 HU in patients allocated control, p = 0.117). In multivariable ordinal regression analysis controlled for patient age, stroke severity, location and extent of obstruction, time from stroke onset to baseline scan and rt-PA treatment allocation, the attenuation of pre-randomization arterial obstruction was not independently associated with six-month outcome (odds ratio = 0.99, 95% confidence interval = 0.94-1.03, p = 0.516).
In ischemic stroke, the x-ray attenuation of the arterial obstruction may decline more rapidly from baseline to 24-48 hours following treatment with thrombolysis but we found no evidence that baseline arterial obstruction attenuation predicts six-month outcome.
评估在缺血性卒中患者中,通过非增强CT测量的动脉内阻塞的X线衰减是否能够预测溶栓治疗的反应及随后的功能结局。
第三次国际卒中试验(IST-3)是一项多中心随机对照试验,研究在缺血性卒中6小时内静脉注射溶栓药物(重组组织型纤溶酶原激活剂,rt-PA)的疗效。试验获得了伦理批准并取得了患者的知情同意。在IST-3研究的109例患者亚组中(38例男性,中位年龄82岁),由一名对所有临床和其他影像资料均不知情的阅片者,在随机分组前以及24 - 48小时随访时,在血管造影证实的动脉内阻塞部位手动测量非增强CT上的X线衰减(亨氏单位,HU)。我们计算了两次扫描之间衰减的变化。我们评估了随机分组前动脉阻塞衰减对6个月功能结局的影响。
大多数动脉阻塞(64/109,59%)表现为高密度(平均51.0 HU)。与对照组相比,rt-PA治疗组在随访时阻塞衰减的降低幅度更大,但差异无统计学意义(对照组患者为-1.4 HU,rt-PA治疗组患者为-8.0 HU,p = 0.117)。在对患者年龄、卒中严重程度、阻塞部位和范围、卒中发作至基线扫描的时间以及rt-PA治疗分配进行控制的多变量有序回归分析中,随机分组前动脉阻塞的衰减与6个月结局无独立相关性(优势比 = 0.99,95%置信区间 = 0.94 - 1.03,p = 0.516)。
在缺血性卒中患者中,动脉阻塞的X线衰减在溶栓治疗后从基线至24 - 48小时可能下降得更快,但我们没有发现证据表明基线动脉阻塞衰减可预测6个月结局。